Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030537 · ClinicalTrials.gov registry record · Phase 2
Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Study locations
NCT00030537: Completed Phase 2 study of Breast Cancer, sponsored by National Cancer Institute (NCI).
NCT00030537 is a Phase 2 study of Breast Cancer that has completed, run by National Cancer Institute (NCI). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00030537, a Phase 2 study of Breast Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have locally advanced or metastatic breast cancer.
Conditions Studied
Interventions
- DRUG erlotinib hydrochloride
Study Locations (2)
Maryland
- Center for Cancer Research - Bethesda
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-11 |
| Est. Completion | 2003-03 |
| Phase | Phase 2 |
What the finished NCT00030537 record still lists
NCT00030537 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which erlotinib hydrochloride is the first listed.
NCT00030537 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00030537 about?
NCT00030537 is a clinical study titled "Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer". RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have locally advanced or metastatic breast cancer.
What is the current status of trial NCT00030537?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-11. Estimated completion is 2003-03.
What conditions does trial NCT00030537 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00030537?
The interventions under investigation include: erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00030537?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00030537 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia